Please login to the form below

Not currently logged in
Email:
Password:

postmenopausal osteoporosis

This page shows the latest postmenopausal osteoporosis news and features for those working in and with pharma, biotech and healthcare.

Amgen and UCB’s Evenity finally approved, but with label warnings

Amgen and UCB’s Evenity finally approved, but with label warnings

The CDER's Hylton Joffe. “Today’s approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk,” said Hylton ... Amgen’s R&D head David Reese welcomed the FDA approval,

Latest news

  • UCB looks to pipeline with five years left for twin blockbusters UCB looks to pipeline with five years left for twin blockbusters

    25%. The first new product to hit the market is osteoporosis candidate Evenity (romosozumab), co-developed and co-marketed with Amgen.  The drug has suffered setbacks in reaching the market, being ... to treat osteoporosis in postmenopausal women at

  • Evenity back on track with FDA panel blessing in osteoporosis Evenity back on track with FDA panel blessing in osteoporosis

    The panel backed the use of the drug in postmenopausal women with osteoporosis at high risk for fracture by 18-1. ... risk. Amgen’s R&D head Davide Reese said that having additional treatment options for postmenopausal women with osteoporosis is

  • Amgen's Kyprolis scarred by head-to-head duel with Velcade Amgen's Kyprolis scarred by head-to-head duel with Velcade

    Romosozumab filed  . There was some better news for Amgen and partner UCB this week when the FDA started its review of romosozumab, their drug candidate for the treatment of osteoporosis in ... postmenopausal women at increased risk of fracture.

  • Merck decision to drop odanacatib lifts UCB/Amgen Merck decision to drop odanacatib lifts UCB/Amgen

    The company prematurely halted a phase III trial of the drug in 2012 after seeing a clear benefit on fractures rates in postmenopausal women with osteoporosis, although it did note at ... fractures in postmenopausal women with osteoporosis compared to

  • Amgen buys back product rights from GSK Amgen buys back product rights from GSK

    The US biopharma giant is reacquiring rights to denosumab - sold as Prolia for osteoporosis and Xgeva for bone metastases from solid tumours - and colorectal cancer therapy Vectibix (panitumumab). ... Meanwhile, Prolia received a boost recently after it

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics